Drugs / EGFRvIII-CARs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03283631 | May 2018 → Sep 2019 | gliosarcoma | Gary Archer Ph.D. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGFRvIII-CARs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03283631 ↗ |
| Modality | Cell therapy | “Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells” NCT03283631 ↗ |
| Route | Other | “a catheter was placed intratumorally for delivery of EGFRvIII-CARs by Convection Enhanced Delivery (CED).” NCT03283631 ↗ |